about
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialMulticenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active thPhase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial.Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study.Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses.Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study.Cancer epidemiology in Central, South and Eastern European countries.PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance.Adjuvant trastuzumab in HER2-positive breast cancer.Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.Prognostic significance of TOP2A gene dosage in HER-2-negative breast cancerReducing the global breast cancer burden: the importance of patterns of care research.Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines.Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients.Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trialHealth-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 StudyA phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients.Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.Trastuzumab treatment in patients with breast cancer and metastatic CNS disease.Doxorubicin and paclitaxel versus fluorouracil, doxorubicin and cyclophosphamide as first-line therapy for women with advanced breast cancer: long-term analysis of the previously published trial.Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancerObesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysisA single-arm phase II trial of first-line paclitaxel in combination with lapatinib in HER2-overexpressing metastatic breast cancer.Clinical evaluation of developed PCR-based method with hydrolysis probes for TOP2A copy number evaluation in breast cancer samples.Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study.HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials.Detection of circulating breast cancer cells in peripheral blood by a two-marker reverse transcriptase-polymerase chain reaction assay.Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial.Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial.Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.ONCOPOOL - a European database for 16,944 cases of breast cancer.Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.Long-term survival in primary breast cancer: correlation with estrogen and progesterone receptor assay results and adjuvant tamoxifen therapy.Delays in diagnosis and treatment of breast cancer: a multinational analysis.
P50
Q27851403-22891FA9-761F-404A-BF32-717245766351Q27851691-1230651C-7281-4B8D-9E83-FF19E955F862Q28254919-3485F391-4A7A-404D-8C8F-3F30CBC9EC45Q33393031-714F202E-95F9-4960-B42D-352A42C6DD14Q33397151-D345A26B-901F-430E-BF6D-C3FB7BFA1D1BQ34172753-1C99F9D2-0ADF-41D0-896D-DDA0BFDD552BQ34658278-5DA83FB8-DF51-45ED-AC41-8A6BB3D4D7F6Q34743488-B7626D0F-99B3-4768-8AD8-5953EE43F499Q34877463-DF114205-1DA9-4931-8EC6-5DE825B98609Q35178383-59935820-9D1D-4D1A-BB7E-3E39261172BCQ35562967-61B3BA77-F741-47DA-B80F-106435FA2EABQ35710898-16CBE2AB-41FE-47E4-922A-87E14AD096E1Q36222669-ACA62901-7E84-4855-8936-95800BA438F8Q36349584-859E775C-6F97-4826-AAD2-80B3DC3517A8Q36355117-C008189E-A0DD-417D-86E6-19F155A5A564Q36593165-60ECA583-7502-47D8-ACB8-439B3A7B3C74Q36644465-888A220C-CCAC-42E2-9D28-226C7E0B87E8Q36651026-3881A9F8-881D-4855-90AD-0421D761C9CBQ36680024-AEBD63F4-AC70-413D-81AC-E76AE9E1E18FQ37038467-CFEC2FF5-33BC-4F7F-85C9-9A175DFD9E0FQ37054957-208FCE98-5105-4512-8B99-C6BA8D2C5430Q37292031-7CC1F097-A6BC-4E8B-A4DC-9CFA932FDE7AQ37577641-E30CFBD2-6C41-46EC-9488-83626EFA97B6Q37589339-1FA9F387-D23E-40E7-BF2C-9DA7273D148EQ37595259-A2A08279-A5D7-48C6-93D0-939A6FCB0D7CQ37633741-04135739-983E-4FE8-BECA-73BBC64FD16BQ37690278-507A0374-6E33-4C67-91BE-4C16E5703022Q37810735-2DDE4D99-F522-48F8-AA5A-7B4639652F24Q38344300-3EB96792-2E34-4980-A14E-1A42848DE23DQ38395226-B1D05B4D-6BD9-48CE-881F-C95363EB311BQ39068453-A9F7035D-11F3-43CE-9B70-B6658613F38DQ39442160-E006019A-DE2C-465B-9DC6-1AAF75252DC4Q40510900-8B14C743-575B-4E23-8400-1F60FDC49997Q40521722-DC5E0D4B-5A89-426A-AD63-D5B31FFED4D4Q40606333-CB291CD0-2C50-438A-89E4-A65E104FEC46Q42627458-678F92DD-C41D-4663-96F6-F8DE1D49EA5AQ43265459-40BEDBB0-1AC9-4E3F-950B-8FC46ECFEB6AQ44362096-0782BB33-377C-4D6A-A1C8-CE871A90EDF5Q45078297-6E25EEA3-7AC5-4565-8EE6-50E74411E9D4Q45976520-6B790B1B-9D7E-4B4F-810D-AA8808D4F636
P50
description
Polish oncologist
@en
Pools onderzoeker
@nl
oncólogo polaco
@es
polski onkolog
@pl
name
Tadeusz Pienkowski
@es
Tadeusz Pienkowski
@sl
Tadeusz Pieńkowski
@ca
Tadeusz Pieńkowski
@de
Tadeusz Pieńkowski
@en
Tadeusz Pieńkowski
@fr
Tadeusz Pieńkowski
@ga
Tadeusz Pieńkowski
@gl
Tadeusz Pieńkowski
@it
Tadeusz Pieńkowski
@nl
type
label
Tadeusz Pienkowski
@es
Tadeusz Pienkowski
@sl
Tadeusz Pieńkowski
@ca
Tadeusz Pieńkowski
@de
Tadeusz Pieńkowski
@en
Tadeusz Pieńkowski
@fr
Tadeusz Pieńkowski
@ga
Tadeusz Pieńkowski
@gl
Tadeusz Pieńkowski
@it
Tadeusz Pieńkowski
@nl
altLabel
Tadeusz Pienkowski
@en
prefLabel
Tadeusz Pienkowski
@es
Tadeusz Pienkowski
@sl
Tadeusz Pieńkowski
@ca
Tadeusz Pieńkowski
@de
Tadeusz Pieńkowski
@en
Tadeusz Pieńkowski
@fr
Tadeusz Pieńkowski
@ga
Tadeusz Pieńkowski
@gl
Tadeusz Pieńkowski
@it
Tadeusz Pieńkowski
@nl
P214
P101
P106
P1412
P1559
Tadeusz Pieńkowski
@pl
P21
P214
P27
P31
P496
0000-0002-0110-5950
P6634
tadeusz-pienkowski-890b3b4
P734
P735
P7859
viaf-302005706